Abstract:Combination therapy, a treatment modality that studies the effect of two or more drugs is the most common strategy used to overcome drug resistance in cancer. Cannabinoids have been proven to be potential anticancer agents. Terpenes have also been demonstrated to exhibit anticancer activity. The purpose of this study was to evaluate the effect of combinations of various cannabinoids and terpenes against drug resistant lung and breast cancer. Several cannabinoids and terpenes such as cannabidiol (CBD), cannabichromene (CBC), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabinol (CBN), cannabigerol (CBG) and β-caryophyllene (BC), bisabolol, myrcene, linalool, limonene, geraniol, neralidol, α-pinene, α-terpineol, γ-terpinene respectively were screened for their anticancer activity against MDA MB 231 DOX RT, H1975 OSM RT, PDX Lung cancer cell lines using 2D cytotoxicity and 3D spheroids assay. It was found that the cytotoxic potential of combinations of cannabinoids with BC increased by 10 folds in comparison to their individual anticancer activity. The combinations that exhibit synergistic action were determined from combination index (CI) values using compusyn software. Other assays such as colony formation, wound healing, apoptotic assay, cell cycle analysis by flow cytometry elucidated the possible mechanism underlying the synergism of the combinations investigated. CBC+BC was proven to be the most potent combination from all the in-vitro studies and hence was further evaluated in in-vivo tumor xenografts. Briefly, 5 million MDA MB 231 DOX RT cells were injected by S.C route in the right flank region of BALB/c nude mice. The animals were treated after the tumor volume reached 180-200mm3. The animals were administered CBC (15mg/kg, i.p.), BC (100mg/kg, i.p.) and CBC+BC thrice a week for two weeks. The tumor volume in the combination group was reduced by 2 folds relative to individual treatments and 4 folds relative to control. Western blot analysis of tumor xenografts showed downregulation of apoptotic markers such as PARP, mTOR, pAMPK, Survivin, autophagy markers such as LC 3, Glypican 5 and migration markers such as vimentin and Integrin. Immune check point proteins such as PD-L1 and PD-1 were also downregulated by combination treatment. This was further validated by qPCR. In conclusion, CBC induces programmed cell death in tumors and induces autophagy whereas BC inhibits migration and thus this combination was able to overcome resistance than individual therapies in a synergistic fashion. Citation Format: Mounika Aare, Islauddin Khan, Aakash Nathani, Breana Boirie, Arvind Bagde, Mandip Singh. Synergistic anticancer activity of cannabinoids and beta caryophyllene in xenograft mouse model of triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4566.

Cannabidiol Inhibits Tumorigenesis in Cisplatin-Resistant Non-Small Cell Lung Cancer via TRPV2

Discovering single cannabidiol or synergistic antitumor effects of cannabidiol and cytokine-induced killer cells on non-small cell lung cancer cells

Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/nitrosative Stress, Inflammation, and Cell Death.

Cannabidiol exhibits potent anti-cancer activity against gemcitabine-resistant cholangiocarcinoma via ER-stress induction in vitro and in vivo

Unravelling the Transcriptomic Impact of Cisplatin and High-THC Cannabis Extract

Cannabinoids Inhibited Pancreatic Cancer via P-21 Activated Kinase 1 Mediated Pathway

Targeting CXCR2 inhibits the progression of lung cancer and promotes therapeutic effect of cisplatin

Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer

Silencing Nrf2 in cisplatin resistant non-small cell lung cancer cells augments sensitivity towards EGFR inhibitor

Cannabidiol's cytotoxicity in pancreatic cancer is induced via an upregulation of ceramide synthase 1 and ER stress

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis

Targeting Mitochondrial IDH2 Enhances Antitumor Activity of Cisplatin in Lung Cancer via ROS-Mediated Mechanism

Abstract 4566: Synergistic anticancer activity of cannabinoids and beta caryophyllene in xenograft mouse model of triple negative breast cancer

Curcumin enhances cisplatin sensitivity of human NSCLC cell lines through influencing Cu-Sp1-CTR1 regulatory loop

Abstract 5548: Cannabidiol enhances efficacy of atezolizumab via upregulation of PD-L1 expression by cGAS-STING pathway in triple negative breast cancer cells

Curcumin Inhibits the Progression of Non-small Cell Lung Cancer by Regulating DMRT3/SLC7A11 Axis

Beta-Caryophyllene Enhances the Anti-Tumor Activity of Cisplatin in Lung Cancer Cell Lines through Regulating Cell Cycle and Apoptosis Signaling Molecules

Capivasertib augments chemotherapy via Akt inhibition in preclinical small cell lung cancer models

Cannabinoid-2 Receptor Limits Inflammation, Oxidative/nitrosative Stress, and Cell Death in Nephropathy

Parthenolide Augments the Chemosensitivity of Non-small-Cell Lung Cancer to Cisplatin via the PI3K/AKT Signaling Pathway

Enhancement of Cisplatin-Induced Cytotoxicity Against Cervical Cancer Spheroid Cells by Targeting Long Non-Coding RNAs.